Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials

被引：1
|
作者：
Mellbin, Linda G. [1 ,2 ]
Bhatt, Deepak L. [3 ]
David, Jens-Peter [4 ]
Ekstrom, Kathrine [4 ]
Petrie, Mark C. [5 ]
Rasmussen, Soren [4 ]
Vilsboll, Tina [6 ]
机构：
[1] Karolinska Inst, Dept Med Solna, Eugeniavagen 27, S-17164 Solna, Stockholm, Sweden
[2] Karolinska Univ Hosp, Heart Vasc & Neuro Theme, K2 Med,K2 Kardio Pernow J, S-17177 Solna, Stockholm, Sweden
[3] Mt Sinai Fuster Heart Hosp, Icahn Sch Med Mt Sinai, New York, NY USA
[4] Novo Nord A S, Soborg, Denmark
[5] Univ Glasgow, Sch Cardiovasc & Metab Hlth, Glasgow City, Scotland
[6] Univ Copenhagen, Steno Diabet Ctr Copenhagen, Clin Res, Copenhagen, Denmark
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷 / 15期
关键词：
Cardiovascular outcomes trial; Glucagon-like peptide-1 receptor agonist; HbA(1c); Major adverse cardiovascular events; PIONEER; 6; Post hoc analysis; Semaglutide; SUSTAIN; Type; 2; diabetes;
D O I：
10.1093/eurheartj/ehae028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1371 / 1374
页数：4
相关论文
共 50 条
  • [21] Effect of semaglutide on MACE by baseline kidney function in participants with type 2 diabetes and high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc analysis
    Rossing, P.
    Bain, S.
    Bosch-Traberg, H.
    Frenkel, O.
    Heerspink, H. L.
    Rasmussen, S.
    Mellbin, L.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S24 - S25
  • [22] APPLYING REWIND CVD CRITERIA TO SUSTAIN 6 AND PIONEER 6: AN EXPLORATORY ANALYSIS OF CV OUTCOMES WITH SEMAGLUTIDE
    Verma, Subodh
    Fainberg, Udi
    Husain, Mansoor
    Rasmussen, Soren
    Ryden, Lars E.
    Ripa, Maria Sejersten
    Buse, John B.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1922 - 1922
  • [23] Neutrophil to lymphocyte ratio predicts cardiovascular events in people with type 2 diabetes: Post hoc analysis of the SUSTAIN 6 and PIONEER 6 cardiovascular outcomes trials
    Verma, Subodh
    Husain, Mansoor
    Madsen, Christian M.
    Leiter, Lawrence A.
    Kuhlman, Anja Birk
    Vilsboll, Tina
    Rasmussen, Soren
    Libby, Peter
    DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2398 - 2401
  • [24] Liraglutide and semaglutide improve cardiovascular and renal outcomes across baseline BP categories: analysis of LEADER and SUSTAIN 6
    Leiter, L. A.
    Bain, S. C.
    Bhatt, D. L.
    Buse, J. B.
    Mazer, C. D.
    Pratley, R.
    Lindberg, S.
    Rasmussen, S.
    Vrazic, H.
    Verma, S.
    DIABETOLOGIA, 2019, 62 : S364 - S365
  • [25] EFFECTS OF SEMAGLUTIDE VERSUS COMPARATORS ON CARDIOVASCULAR EVENTS ACROSS A CONTINUUM OF BASELINE CARDIOVASCULAR RISK: COMBINED ANALYSIS OF THE SUSTAIN AND PIONEER TRIALS
    Husain, Mansoor
    Bain, Stephen C.
    Holst, Anders G.
    Mark, Thomas
    Rasmussen, Soren
    Lingvay, Ildiko
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1909 - 1909
  • [26] Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials
    Strain, W. D.
    Holst, A. G.
    Rasmussen, S.
    Saevereid, H. A.
    James, M. A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S130 - S131
  • [27] Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials
    Strain, W. D.
    Holst, A. G.
    Rasmussen, S.
    Saevereid, H. A.
    James, M. A.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2424 - 2424
  • [28] Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
    Peter Rossing
    Stephen C. Bain
    Heidrun Bosch-Traberg
    Ekaterina Sokareva
    Hiddo J. L. Heerspink
    Søren Rasmussen
    Linda G. Mellbin
    Cardiovascular Diabetology, 22
  • [29] Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
    Rossing, Peter
    Bain, Stephen C.
    Bosch-Traberg, Heidrun
    Sokareva, Ekaterina
    Heerspink, Hiddo J. L.
    Rasmussen, Soren
    Mellbin, Linda G.
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [30] Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
    Husain, Mansoor
    Consoli, Agostino
    De Remigis, Alessandra
    Meyer, Anna Sina Pettersson
    Rasmussen, Soren
    Bain, Stephen
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
12345